Boston Scientific Corporation $BSX Shares Purchased by Clearbridge Investments LLC

Clearbridge Investments LLC increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 25,528.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 733,237 shares of the medical equipment provider’s stock after purchasing an additional 730,376 shares during the period. Clearbridge Investments LLC’s holdings in Boston Scientific were worth $69,914,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Syon Capital LLC increased its position in Boston Scientific by 2.5% during the fourth quarter. Syon Capital LLC now owns 27,901 shares of the medical equipment provider’s stock worth $2,660,000 after purchasing an additional 691 shares during the last quarter. Capital World Investors increased its position in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Capital Research Global Investors increased its position in shares of Boston Scientific by 6.8% during the fourth quarter. Capital Research Global Investors now owns 7,084,055 shares of the medical equipment provider’s stock valued at $675,467,000 after acquiring an additional 450,322 shares during the last quarter. Capital International Sarl increased its position in shares of Boston Scientific by 26.6% during the fourth quarter. Capital International Sarl now owns 415,718 shares of the medical equipment provider’s stock valued at $39,639,000 after acquiring an additional 87,427 shares during the last quarter. Finally, Capital International Ltd. CA increased its position in shares of Boston Scientific by 17.3% during the fourth quarter. Capital International Ltd. CA now owns 238,865 shares of the medical equipment provider’s stock valued at $22,776,000 after acquiring an additional 35,274 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 9,800 shares of company stock worth $554,012 over the last 90 days. 0.34% of the stock is owned by insiders.

Boston Scientific Trading Up 0.4%

NYSE BSX opened at $48.73 on Tuesday. The firm has a 50 day simple moving average of $57.68 and a 200-day simple moving average of $76.17. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a one year low of $47.17 and a one year high of $109.50. The firm has a market cap of $72.42 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 0.91 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the firm posted $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BSX. Mizuho dropped their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a research report on Thursday, April 23rd. Finally, Bank of America dropped their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $85.92.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.